Emerging biopharma approaching its first commercial launch
FDA clearance is closer than expected.
The organization has never commercialized in-house.
The CEO is asking:
"Are we ready?"
Not as a rhetorical question. As the kind that keeps her up at night.
Where Alexander Jamison comes in:
Builds the governance infrastructure before launch exposes what the organization does not yet have.
Mid-size biopharma with a 2nd asset on a compressed timeline
The first launch worked well enough.
But leadership knows where the organization struggled.
Now there are two assets, one commercial organization, and a timeline that will not allow the same improvisation.
Where Alexander Jamison comes in:
Identifies what broke in the first launch — and designs the architecture that holds under the demands of the second
VC- or PE-backed org under increasing investor scrutiny
The board is asking harder questions.
Portfolio prioritization.
Resource allocation.
Commercial readiness.
The CEO needs to answer with clarity — not just confidence.
Where Alexander Jamison comes in:
Designs governance and enterprise visibility architecture that makes board conversations structured, defensible, and proactive.
Organization that experienced friction in its last launch
Decision cycles elongated.
Cross-functional alignment broke down at critical moments.
The right people were not always in the right rooms.
Leadership knows what went wrong.
But the architecture to prevent it from happening again does not yet exist.
Where Alexander Jamison comes in:
Identifies the structural causes of the friction — and designs the system that fixes the root, not the symptom.
Scaling commercial operations from domestic to international
A second geography exposes governance gaps that proximity and informal coordination once hid.
What worked in one market will not work in two.
Where Alexander Jamison comes in:
Designs governance architecture that scales across markets without losing accountability or decision velocity.